Journal of Medicinal Chemistry: Discovery of Cell-Permeable Macrocyclic Cyclin A/B RxL Inhibitors that Demonstrate Antitumor Activity May 7, 2026 READ MORE
AACR 2026: Discovery of CID-078, a first-in-class oral macrocycle cyclin A/B-RxL inhibitor, for the treatment of cancers with Rb-deficiency or hyperactivated E2F April 20, 2026 READ MORE
AACR 2026: Early clinical activity from the phase 1 evaluation of CID-078, a novel cyclin A/B RxL inhibitor, in patients with advanced solid tumors April 19, 2026 READ MORE
AACR 2026: Orally bioavailable peptide macrocycles disrupting intracellular protein-protein interactions: selective inhibitors of the RxL binding site of cyclin family proteins April 18, 2026 READ MORE
Circle Pharma Announces Publication in Journal of Medicinal Chemistry Highlighting Optimization of First-in-Class Oral Cyclin A/B RxL Inhibitors March 12, 2026 READ MORE
Journal of Medicinal Chemistry: Orally Bioavailable Cyclin A/B RxL Inhibitors: optimization of a novel class of macrocyclic peptides to target E2F high and G1–S-checkpoint compromised cancers February 21, 2026 READ MORE
